(1)
Novel Approach Successfully Induces Regression of Established Tumors by Focusing Immunotherapy to Target Achilles Heel of Cancer
HOUSTON, Feb. 17, 2021 /PRNewswire/ FibroGenesis, a clinical stage company developing fibroblast-based therapeutic solutions for unmet medical needs, announced today new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer.
Company scientists successfully replicated the process by which cancer coaxes fibroblasts to support its growth. By manipulating these artificially generated cancer-associated-fibroblasts (CAFs) , the Company was able to generate an immunotherapy that teaches the immune system to selectively kill only fibroblasts which help tumors to grow.